Most coverage of retatrutide has fixated on one number: the weight loss. But the more consequential story in the retatrutide phase 3 TRIUMPH programme is structural. Eli Lilly didn't build TRIUMPH as a weight-loss programme with some extra endpoints bolted on. It built a basket trial — a pivotal package designed to generate registration-grade evidence for obesity, obstructive sleep apnoea and knee osteoarthritis simultaneously, before the drug has been approved anywhere for anything.

That is a different playbook to the one used for every incretin drug before it, and the design rationale is now on the record in a peer-reviewed paper in Diabetes, Obesity and Metabolism.

What the retatrutide phase 3 TRIUMPH programme is actually testing

Per the published design paper, TRIUMPH comprises four Phase 3 randomised, double-blind, placebo-controlled studies of once-weekly subcutaneous retatrutide in more than 5,800 participants:

  • TRIUMPH-1 and TRIUMPH-2 — weight-management trials with OSA and/or knee OA protocols nested inside them
  • TRIUMPH-3 — weight management in people with established cardiovascular disease
  • TRIUMPH-4 — a standalone knee osteoarthritis trial

The primary endpoint for weight management is percent change in body weight; for OSA it's change in the Apnoea–Hypopnoea Index (AHI); for knee OA it's change in the WOMAC pain subscale. Critically, the statistical architecture allows each basket to be analysed independently, with type I error controlled at α = 0.05 and split between the overarching weight-management study and each nested basket. In plain terms: the sleep apnoea result can stand on its own feet rather than being dismissed as an exploratory afterthought.

If you're new to the molecule, our what is retatrutide explainer covers the GLP-1 + GIP + glucagon triple-agonist mechanism, and clinical trials tracks the programme trial by trial.

Why this differs from tirzepatide and semaglutide

Tirzepatide and semaglutide both earned their complication-specific evidence after they were already approved for weight management. SURMOUNT-OSA — the tirzepatide sleep apnoea programme — and STEP 9 — the semaglutide knee OA study — were run as separate registrational trials once the drugs were on the market, as the TRIUMPH design paper notes.

Retatrutide is attempting to arrive with that evidence already in hand. Whether regulators grant multiple indications off a single pivotal package is their call, not Lilly's, and nothing in the published material guarantees that outcome.

The sleep apnoea signal inside TRIUMPH-1

In the moderate-to-severe OSA basket nested within TRIUMPH-1 — 243 participants, baseline AHI 58.6 events per hour, which is severe — retatrutide 12 mg reduced AHI by 36.1 events per hour, a 60.6% reduction, at 80 weeks. Lilly also reported improvement in knee osteoarthritis pain of up to 73.1% in the OA basket.

Two caveats worth stating plainly. First, these figures come from a Lilly press release and a conference presentation at the ADA 86th Scientific Sessions, not from a full peer-reviewed publication of the results. Second, a baseline AHI of 58.6 is high, and absolute event reductions scale with how bad your starting point is — which makes casual cross-trial comparison misleading.

The tirzepatide comparison, done honestly

For reference, the SURMOUNT-OSA trials published in the New England Journal of Medicine found tirzepatide reduced AHI by a mean of 25.3 events per hour in participants not using positive airway pressure and 29.3 events per hour in those on PAP, versus 5.3 and 5.5 events per hour on placebo, at 52 weeks.

You cannot read across from that to retatrutide's 36.1. Different trials, different populations, different baseline severity, different durations (52 weeks versus 80), no shared control arm. A head-to-head trial of retatrutide against tirzepatide in OSA does not exist. Anyone presenting these numbers as a ranking is over-reading the data.

Why the basket design matters for patients, not just regulators

Obesity, sleep apnoea and knee osteoarthritis travel together, and each is usually managed by a different specialty with a different treatment: weight management, CPAP, analgesia and eventually joint replacement. A single pivotal programme that measures all three at once is an argument that they should be treated as one problem with one upstream driver.

For the headline efficacy context: TRIUMPH-1 reported average body weight reduction of up to ~28.3% at the 12 mg dose over 80 weeks, with 45.3% of participants losing 30% or more of body weight. Gastrointestinal adverse events — nausea, diarrhoea, vomiting, constipation — were the most common and were dose-related; see safety for the detail.

The Australian read

Retatrutide is investigational and not TGA-approved for any indication in Australia, and Lilly has signalled regulatory filings from 2027. If the OSA and OA baskets do carry through to approved indications overseas, they will eventually form part of whatever dossier the TGA assesses — but that is a downstream question, and nothing about the sequence or timing of an Australian submission has been announced. Our Australia page tracks the local status as it changes.

Want the next TRIUMPH readout in your inbox rather than your feed? Join the free updates list.

FAQ

What is the TRIUMPH basket trial design?

TRIUMPH is Lilly's Phase 3 retatrutide programme: four randomised, double-blind, placebo-controlled trials in over 5,800 participants, in which obstructive sleep apnoea and knee osteoarthritis sub-studies are nested inside the weight-management trials, with statistical error control split so each can be analysed independently.

Does retatrutide help sleep apnoea?

In the moderate-to-severe OSA basket inside TRIUMPH-1 (243 participants), retatrutide 12 mg reduced the Apnoea–Hypopnoea Index by 36.1 events per hour — a 60.6% reduction — at 80 weeks. That result was reported via company press release and conference presentation, not yet a full peer-reviewed publication.

Is retatrutide better than tirzepatide for sleep apnoea?

Unknown. No head-to-head trial exists. SURMOUNT-OSA reported tirzepatide reducing AHI by 25.3 and 29.3 events per hour at 52 weeks in two cohorts, but the trials differ in population, baseline severity and duration, so the numbers are not directly comparable.

When will retatrutide be approved?

Retatrutide is not approved in any jurisdiction. Eli Lilly has indicated regulatory submissions beginning in 2027; approval decisions rest with each regulator, including the TGA in Australia, and no timeline has been confirmed.

Sources

This article is independent editorial content and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. This is general information only and is not medical advice — talk to your GP or a qualified health professional about your own circumstances.